title: Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery.
abstract: OBJECTIVE
  To observe the efficacy and side effects of adjuvant dendritic cells' (DCs) vaccine combined with cytokine-induced killer cell (CIK) therapy after renal cell carcinoma (RCC) surgery (RCCS).
  
  
  METHODS
  DCs vaccine and CIK that loaded the autologous tumor cell lysate were prepared in vitro. Four hundred and ten RCC patients were recruited, and the study group was given DCs-CIK immunotherapy, while the control group was given IFN-α therapy.
  
  
  RESULTS
  Disease progression (recurrence, metastasis or death) showed significant differences between the two groups in clinical stage I and II patients, as well as in highly and moderately differentiated disease (p<0.05), while there was no significant difference between the two groups in patients with poorly differentiated disease (p>0.05). The 3- and 5-year overall survival rates of the DCs-CIK group (96% and 96%, respectively) exhibited significant difference compared to the IFN-α group (83% and 74%, respectively (p<0.01). Progression-free survival (PFS) between the two groups was significantly different (p<0.01). Tumor stage and DCs-CIK treatment were independent factors concerning prognosis of RCC (p<0.05). There was no severe toxicity observed in the DCs-CIK treatment group.
  
  
  CONCLUSIONS
  Adjuvant post-RCCS DCs-CIK treatment prolonged PFS and reduced mortality, showing better overall activity compared to interferon treatment.
authors.affiliation: Department of Urology, Fuzhou General Hospital, Fuzhou 350025, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Zheng
authors.forename: Jian-Ming
authors.initials: JM
authors.lastname: Tan
authors.forename: Wei-Zhen
authors.initials: WZ
authors.lastname: Wu
authors.forename: Yu-Miao
authors.initials: YM
authors.lastname: Qiu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Ting-Zhao
authors.initials: TZ
authors.lastname: Xu
authors.forename: Xing-Hui
authors.initials: XH
authors.lastname: Sun
authors.forename: Wen-Li
authors.initials: WL
authors.lastname: Zhuo
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D055612:Cytokine-Induced Killer Cells / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D019496:Cancer Vaccines; D016898:Interferon-alpha